MedKoo Cat#: 598167 | Name: Butalamine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Butalamine HCl is a vasodilator (peripheral) with local anesthetic effects. Butalamine HCl has been shown to inhibit state 3 respiration and decrease ADP/O in rat liver.

Chemical Structure

Butalamine HCl
Butalamine HCl
CAS#56974-46-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 598167

Name: Butalamine HCl

CAS#: 56974-46-0 (HCl)

Chemical Formula: C18H29ClN4O

Exact Mass: 0.0000

Molecular Weight: 352.90

Elemental Analysis: C, 61.26; H, 8.28; Cl, 10.05; N, 15.88; O, 4.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Butalamine hydrochloride; Butalamine HCl; Adrevil; LA 1221; Hemotrope;
IUPAC/Chemical Name
N1,N1-dibutyl-N2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethane-1,2-diamine hydrochloride
InChi Key
ZCEDBAQIHPGWNW-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H28N4O.ClH/c1-3-5-13-22(14-6-4-2)15-12-19-18-20-17(21-23-18)16-10-8-7-9-11-16;/h7-11H,3-6,12-15H2,1-2H3,(H,19,20,21);1H
SMILES Code
CCCCN(CCNC1=NC(C2=CC=CC=C2)=NO1)CCCC.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 352.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tine J, Junien JL. Effects of butalamine on oxydative phosphorylations in the rat liver. Arzneimittelforschung. 1976;26(9):1677-80. PubMed PMID: 826262. 2: Morgon A. [Test of butalamine in labyrinth diseases]. JFORL J Fr Otorhinolaryngol Audiophonol Chir Maxillofac. 1976 May;25(5):395-8. French. PubMed PMID: 133207. 3: Traissac L. [Clinical trial of butalamine]. Rev Laryngol Otol Rhinol (Bord). 1973 Sep-Oct;94(9):465-72. French. PubMed PMID: 4603409. 4: Coupar IM, Hedges A, Metcalfe HL, Turner P. Effect of aminophylline, butalamine and imolamine on human isolated smooth muscle. J Pharm Pharmacol. 1969 Jul;21(7):474-5. PubMed PMID: 4390076. 5: Zeitler E. [Xenon-133 muscle clearance before and after butalamine hydrochloride. Results of a double blind test]. Fortschr Med. 1976 Dec 2;94(34):2055-8. German. PubMed PMID: 826469. 6: Sterne J. [Prolonged treatment of obliterantive arteritis with butalamine. Follow up study of 42 cases during more than 1 year of rheographic control]. Rev Clin Esp. 1979 Oct 31;155(2):123-6. Spanish. PubMed PMID: 119287. 7: Sterne J. [Butalamine hydrochloride. A new vasoactive substance]. Fortschr Med. 1976 Apr 15;94(11):657-9. German. PubMed PMID: 823083. 8: Seboldt H. [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride]. Fortschr Med. 1980 Feb 21;98(7):257-60. German. PubMed PMID: 6767648. 9: Zmigrodzka K. [Surheme (Butalamine) in the treatment of vertigo]. Otolaryngol Pol. 1976;30(3):227-33. Polish. PubMed PMID: 823509. 10: Kling H. [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl]. Fortschr Med. 1979 May 17;97(19):926-8. German. PubMed PMID: 109382. 11: Bopp J. [Therapy of arterial-circulation disorders in the legs. Muscle-ergometric studies under the effects of butalamine hydrochloride in a double-blind trial]. Fortschr Med. 1976 Apr 22;94(12):725-7. German. PubMed PMID: 823084. 12: Belousov IuB, Savenkov PM, Sidel'man AA, Parfenov AS, Savenkov MP. [Pharmacotherapy of peripheral arteriosclerosis]. Kardiologiia. 1978 Aug;18(8):36-43. Russian. PubMed PMID: 99596.